 |
|
|
| |
Dolutegravir-based Simplified Maintenance Therapy in HIV-infected Patients
a Systematic Review and Meta-analysis
|
| |
| |
Reported by Jules Levin
EACS - 16th European AIDS Conference, October 25-27, 2017. Milan
M. Buzzi, G. Wandeler,
N. Anderegg, D. Sculier, C. Béguelin, M. Egger, A. Calmy
SWORD 1 & 2: Switch to DTG + RPV Maintains Virologic Suppression Through 48 Weeks, a Phase III Study - (02/16/17)
ACTG A5353: A pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/ml - (07/31/17)
Dolutegravir-Lamivudine as initial therapy in HIV-1 infected, ARV-naïve patients: 96 week results of the PADDLE trial - (07/25/17)
Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study - (07/24/17)
Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial - (07/27/17)
Darunavir/Ritonavir Plus 3TC Noninferior to Triple Therapy at 24 Weeks - ANDES Study - A Phase 4, Randomized, Open Label, Study of a Ritonavir-Boosted Darunavir in Fixed Dose Combination (FD-DRV/r) plus Lamivudine Versus FD-DRV/r plus Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects - (07/23/17)
|
| |
|
|
|
|
|
